Advertisement

Topics

Amgen’s Challenge Over Sensipar Pediatric Exclusivity Moves To US Appeals Court

19:21 EDT 17 May 2018 | SCRIP

Amgen asserts FDA improperly tied pediatric exclusivity denial to lack of meaningful labeling resulting from the studies; justices question whether...

      

Related Stories

 

Original Article: Amgen’s Challenge Over Sensipar Pediatric Exclusivity Moves To US Appeals Court

NEXT ARTICLE

More From BioPortfolio on "Amgen’s Challenge Over Sensipar Pediatric Exclusivity Moves To US Appeals Court"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...